IBL International has entered a strategic collaboration with healthcare company Grifols to develop biomarker panels for ...

IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a ...

Under this collaboration, IBL will develop biomarker panels for specialty diagnostics based on Grifols’ random access, single ...

Brookfield had filed a non-binding offer on Nov. 19 for Grifols that valued the developer of human plasma-based drugs at ...

We recently published a list of 11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts. In this article, we are ...

Pharma and biotech companies are breathing a sigh of relief after the tariffs announced by President Donald Trump Wednesday afternoon excludes pharmaceuticals.

Patients with hereditary angioedema who switched from other drugs to donidalorsen for long-term prophylaxis experienced fewer attacks and improved disease control, according to a poster presented here ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.

Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify early biological signals of Parkinson’s ...